Banking on exosomes

How Alxerion is mining its biobank of exosomes for cancer discovery

Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer.

The company aims to collect and screen 350,000 samples from 30,000 species encompassing a wide range of symbiotic and competing life forms. Exosomes from natural competitors could contain agents with antibiotic, antifungal, antiproliferative or anti-inflammatory properties.

“The pharmaceutical industry strayed away from new

Read the full 660 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE